Cannabinoid Encyclopedia

Cannabinoid guide

What is CBC?

CBC is a minor, non-intoxicating cannabinoid found in cannabis. People most often ask about it in connection with pain, inflammation, skin, and mood or brain research. Those are early research questions, not established CBC benefits in people.

Updated July 2026 83 research sources Human and early research

The short answer

CBC, in simple terms

CBC is interesting because it shows biological activity, but no broad health benefit has been established for CBC in people. 1 2 3

The research that creates interest in CBC is mostly cell, animal, and mechanism work. The small human evidence base often involves multi-cannabinoid products, so it cannot tell us what CBC alone does. 1 2 3

What this means: CBC is worth reading about as an early-stage cannabinoid. It is not yet possible to turn the pain, inflammation, skin, or mood research into a general promise about what CBC will do for a person. 1 2 3

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about CBC.

Why people look into itSee the main questions before the research details. What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Why people look into CBC

What CBC is commonly talked about for

CBC comes up most often in conversations about pain, inflammation, skin, and mood or brain health. The important distinction is that interest in an area does not mean CBC has been shown to work for that area in people.

  1. Early animal and mechanism research

    Pain

    CBC has been tested in pain models and in studies of sensory signaling. That explains the interest, but it does not establish pain relief for people. 2 source

    Read the research

  2. Early animal and cell research

    Inflammation

    Researchers study CBC alongside inflammatory pathways and immune signals. Those results are not the same as evidence that it treats an inflammatory condition. source source

    Read the research

  3. Early skin-biology research

    Skin

    Interest comes from human skin-cell models that examine endocannabinoid and inflammatory signaling, plus a mouse dermatitis model that examined Th2 cytokines and JAK/STAT activity. Those mechanisms and models are not evidence of a skin-treatment benefit in people. source source source

    Read the research

  4. Early non-human research

    Mood and brain biology

    CBC has been explored in cell and animal studies involving neural cells, mood-like behavior, and signaling. That work does not show a human mental-health benefit. source source

    Read the research

  5. Limited CBC-specific human evidence

    Safety

    The available safety literature often involves products with more than one cannabinoid. It cannot provide a universal safety answer for CBC alone. 5 3

    Read the research

Bottom line: The useful starting point is not “What does CBC do?” but “Which CBC question do I mean?” The answer changes when you separate a laboratory signal, an animal result, a mixed-cannabinoid product, and a CBC-only human study.

Key takeaways

What to know first

  1. 1

    CBC is a minor cannabinoid generally described as non-intoxicating, unlike THC. 1

  2. 2

    The main reasons people look into CBC are pain, inflammation, skin, and mood or brain research, but the supporting studies are mostly not human clinical trials. 2

  3. 3

    A CBC-containing product, a laboratory result, and a CBC-only human study are different kinds of evidence and should not be treated as the same result. 3

Choose your question

What do you want to know about CBC?

Open the specific research question. A promising biology finding is not the same as a human benefit or a personal safety answer.

  1. 01Reader question

    What is CBC?

    Start with the plain-English identity and the limits of the current evidence.

    Explore the evidence
  2. 02Reader question

    Could CBC help with pain?

    See why the pain discussion is mostly based on non-human research.

    Explore the evidence
  3. 03Reader question

    What about inflammation?

    Separate inflammation models from evidence of a benefit in people.

    Explore the evidence
  4. 04Reader question

    Why is CBC discussed for skin?

    Read the early skin biology and topical research without treating it as a condition claim.

    Explore the evidence
  5. 05Reader question

    What about mood or brain effects?

    Explore the early neural and behavioral research and its limits.

    Explore the evidence
  6. 06Reader question

    What do we know about safety?

    See why a CBC-specific safety answer is still limited.

    Explore the evidence

Research areas

What has CBC been studied for?

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Mostly mechanism-focused

Receptors, transporters, and pharmacology

Studies connect CBC with Receptors, transporters, and pharmacology at the level of receptors, enzymes, signaling, or pharmacology. This helps explain how the biology might work, but it does not prove a health outcome. 4

Human and early-stage research

Safety, tolerability, adverse events, impairment, toxicity, and formulation concerns

Researchers have examined CBC in connection with Safety, tolerability, adverse events, impairment, toxicity, and formulation concerns. The studies may differ in compound, formulation, dose, route, population, and outcome. 3

Human and early-stage research

Skin and inflammatory dermatology

Researchers have examined CBC in connection with Skin and inflammatory dermatology. The studies may differ in compound, formulation, dose, route, population, and outcome. 3

Human and early-stage research

Pain-related outcomes

Researchers have examined CBC in connection with Pain-related outcomes. The studies may differ in compound, formulation, dose, route, population, and outcome. 4

Preclinical and mechanism-focused

Neurobehavioral, mood, neural stem cell, or neurogenesis outcomes

Researchers have examined CBC in connection with Neurobehavioral, mood, neural stem cell, or neurogenesis outcomes. The studies may differ in compound, formulation, dose, route, population, and outcome. 2

Human and early-stage research

Inflammation-related outcomes

Researchers have examined CBC in connection with Inflammation-related outcomes. The studies may differ in compound, formulation, dose, route, population, and outcome. 4

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

23 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

20 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

31 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

Another 9 of 83 research sources could not be placed cleanly into those three groups from the recorded study details.

What these studies actually looked at

The research on CBC is not one kind of study. This source set includes 26 animal studies, 18 narrative or expert reviews, 16 cell or laboratory studies, and 2 clinical studies in people. 3

The recorded populations or models include people or patients (26 sources), animal models (17 sources), and cells or tissue models (10 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is receptor, transporter, target, metabolic, or pharmacology mechanisms (26 sources), safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns (21 sources), and skin, dermatology, antimicrobial, or topical inflammatory outcomes (21 sources). Closely related outcome names can still describe different measurements. 5

The CBC source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

Cannabigerol and cannabichromene in Cannabis sativa L.

On this page, this source examines CBC activity involving receptor, transporter, target, metabolic, or pharmacology mechanisms and CBC and neurobehavioral, mood, neural stem cell, or neurogenesis outcomes. 1

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
receptor, transporter, target, metabolic, or pharmacology mechanisms and neurobehavioral, mood, neural stem cell, or neurogenesis outcomes
Evidence stage
evidence still limited

animal study

Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.

On this page, this source examines CBC and inflammation-related outcomes, CBC and pain-related outcomes, and CBC and neurobehavioral, mood, neural stem cell, or neurogenesis outcomes. 2

Study type
animal study
Population or model
people or patients
Outcome focus
inflammation-related or pain-related outcomes and pain-related outcomes and other recorded details
Evidence stage
mechanism-focused research

cell or laboratory study

Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.

On this page, this source examines CBC and safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns and CBC and skin and inflammatory dermatology. 3

Study type
cell or laboratory study
Population or model
people or patients
Outcome focus
safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns and skin, dermatology, antimicrobial, or topical inflammatory outcomes
Evidence stage
mechanism-focused research

narrative or expert review

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.

On this page, this source examines CBC and inflammation-related outcomes, CBC activity involving receptor, transporter, target, metabolic, or pharmacology mechanisms, and CBC and pain-related outcomes. 4

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
inflammation-related or pain-related outcomes and receptor, transporter, target, metabolic, or pharmacology mechanisms and other recorded details
Evidence stage
evidence still limited

clinical study in people

The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial.

On this page, this source examines CBC and safety, adverse-event, impairment, or formulation-specific concerns and CBC and safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns. 5

Study type
clinical study in people
Population or model
people or patients
Outcome focus
safety, adverse-event, impairment, or formulation-specific concerns and safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns
Evidence stage
human research

Safety and limits

What should readers keep in mind?

Research on CBC should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 3

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What is CBC?

CBC, short for cannabichromene, is a cannabinoid found in cannabis. It is generally described as non-intoxicating, unlike THC. 7

What is CBC supposed to do?

CBC is commonly discussed in connection with pain, inflammation, skin, and mood or brain research. Those are areas being studied, not proven human benefits. 8

Does CBC have proven health benefits?

No broad CBC health benefit is established by the current human evidence. Much of the research is from laboratory or animal studies, and the limited human work often includes other cannabinoids. 9

Is CBC safe?

CBC-specific safety evidence is limited. Product ingredients, dose, route, other medications, and the person using it can all change the safety question. 10

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Cannabigerol and cannabichromene in Cannabis sativa L. narrative or expert review; evidence still limited PubMed 36654096 DOI 10.2478/acph-2021-0021
  2. 2
    Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. animal study; mechanism-focused research PubMed 41680865 DOI 10.1186/s42238-025-00384-7
  3. 3
    Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine. cell or laboratory study; mechanism-focused research PubMed 42163693 DOI 10.2174/0109298673390667251201115054
  4. 4
    Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. narrative or expert review; evidence still limited PubMed 21749363 DOI 10.1111/j.1476-5381.2011.01238.x
  5. 5
    The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. clinical study in people; human research PubMed 37162192 DOI 10.1080/27697061.2023.2203221
  6. 6
    Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae. evidence still limited PubMed 39808700 DOI 10.1021/acssynbio.4c00721
  7. 7
    A systematic review of analytical methodologies capable of analysing phytocannabinoids in cosmetics. systematic review or meta-analysis; evidence still limited PubMed 38229238 DOI 10.1002/dta.3628
  8. 8
    Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms. systematic review or meta-analysis; evidence still limited PubMed 40967679 DOI 10.1016/bs.pbr.2025.07.006
  9. 9
    Broad-spectrum bactericidal synergy of silver-cannabichromene-cannabigerol triple combinations against healthcare-associated pathogens. human research PubMed 41983582 DOI 10.1093/jambio/lxag092
  10. 10
    Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs. clinical study in people; mechanism-focused research PubMed 33134364 DOI 10.3389/fvets.2020.583404
  11. 11
    Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study. human research PubMed 41213439 DOI 10.1016/j.jep.2025.120856
  12. 12
    Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract. human research PubMed 42057192 DOI 10.1186/s42238-026-00432-w
See all 83 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. narrative or expert review; evidence still limited / 3 linked research notes PubMed 21749363
  2. Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. animal study; mechanism-focused research / 3 linked research notes PubMed 41680865
  3. The Mechanism of Cannabichromene and Cannabidiol Alone Versus in Combination in the Alleviation of Arthritis-Related Inflammation. animal study; preclinical research / 2 linked research notes PubMed 37332213
  4. Therapeutic potential of acidic cannabinoids: an update. narrative or expert review; evidence still limited / 1 linked research note PubMed 41545891
  5. Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study. human research / 2 linked research notes PubMed 41213439
  6. Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis. animal study; preclinical research / 2 linked research notes PubMed 39921943
  7. Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. cell or laboratory study; mechanism-focused research; evidence still limited / 2 linked research notes PubMed 37764262
  8. Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation. animal study; mechanism-focused research / 2 linked research notes PubMed 41256665
  9. Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation. animal study; mechanism-focused research / 2 linked research notes PubMed 42139799
  10. The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. clinical study in people; human research / 2 linked research notes PubMed 37162192
  11. Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents. animal study; preclinical research / 3 linked research notes PubMed 40580638
  12. CBD, a precursor of THC in e-cigarettes. evidence still limited / 2 linked research notes PubMed 33903673
  13. Cannabichromene Racemization and Absolute Stereochemistry Based on a Cannabicyclol Analog. evidence still limited / 1 linked research note PubMed 34078070
  14. Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae. evidence still limited / 2 linked research notes PubMed 39808700
  15. In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters. cell or laboratory study; evidence still limited; mechanism-focused research / 3 linked research notes PubMed 35306000
  16. Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine. cell or laboratory study; mechanism-focused research / 2 linked research notes PubMed 42163693
  17. Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract. human research / 1 linked research note PubMed 42057192
  18. The Potential of Cannabichromene (CBC) as a Therapeutic Agent. narrative or expert review; evidence still limited / 3 linked research notes PubMed 38777605
  19. Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. narrative or expert review; evidence still limited / 2 linked research notes PubMed 40872492
  20. Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. narrative or expert review; evidence still limited / 2 linked research notes PubMed 37630401
  21. A systematic review of analytical methodologies capable of analysing phytocannabinoids in cosmetics. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 38229238
  22. Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. animal study; preclinical research / 1 linked research note PubMed 37721989
  23. The antinociceptive activity and mechanism of action of cannabigerol. animal study; preclinical research / 3 linked research notes PubMed 36916438
  24. Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy? narrative or expert review; evidence still limited / 2 linked research notes PubMed 37414155
  25. Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects. cell or laboratory study; evidence still limited / 1 linked research note PubMed 42352060
  26. Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era. narrative or expert review; evidence still limited / 1 linked research note PubMed 32628766
  27. Cannabis Vaping: Existing and Emerging Modalities, Chemistry, and Pulmonary Toxicology. evidence still limited / 1 linked research note PubMed 34622654
  28. Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs. clinical study in people; mechanism-focused research / 1 linked research note PubMed 33134364
  29. Pre-puberty cannabichromene exposure modulates reproductive function via alteration of spermatogenesis, steroidogenesis, and eNOS pathway metabolites. animal study; evidence still limited / 1 linked research note PubMed 37396845
  30. Genotoxicity of selected cannabinoids in human lymphoblastoid TK6 cells. cell or laboratory study; evidence still limited / 1 linked research note PubMed 39172143
  31. Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol. mechanism-focused research / 1 linked research note PubMed 20619971
  32. Mapping the research landscape of minor cannabinoids: a bibliometric analysis of research trends and hotspots. mechanism-focused research / 1 linked research note PubMed 41668212
  33. Development and validation of a fit-for-purpose UHPLC-ESI-MS/MS method for the quantitation of cannabinoids in different matrices. cell or laboratory study; evidence still limited / 1 linked research note PubMed 36854205
  34. Pharmacokinetics of Non-Psychotropic Phytocannabinoids. narrative or expert review; evidence still limited / 1 linked research note PubMed 40006604
  35. Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 40967679
  36. Molecular Pharmacology of Phytocannabinoids. narrative or expert review; evidence still limited / 1 linked research note PubMed 28120231
  37. Cannabinoids, inflammation, and fibrosis. narrative or expert review; evidence still limited / 1 linked research note PubMed 27435265
  38. Cannabis: Chemistry, extraction and therapeutic applications. narrative or expert review; evidence still limited / 1 linked research note PubMed 34838836
  39. The Pharmacology of Cannabinoids in Chronic Pain. narrative or expert review; evidence still limited / 2 linked research notes PubMed 40046175
  40. Effects of cannabidiol, cannabichromene, cannabidivarin, cannabigerol and cannabinol in endometrial cells: Implications for endocrine and senescence modulation. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 40706771
  41. Cannabigerol and cannabichromene in Cannabis sativa L. narrative or expert review; evidence still limited / 2 linked research notes PubMed 36654096
  42. Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models. animal study; evidence still limited; mechanism-focused research / 3 linked research notes PubMed 39769302
  43. Cannabichromene is a cannabinoid CB2 receptor agonist. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 31368508
  44. Effect of Quantitative Structural Properties and Drug Formulation in Four Cannabinoids (Cannabidiol, Cannabigerol, Cannabichromene, and Cannabinol) on Their Lymphatic Transport after Enteral Administration in Rats. animal study; evidence still limited / 1 linked research note PubMed 40611782
  45. Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome. animal study; evidence still limited / 1 linked research note PubMed 33395525
  46. Cannabichromene: integrative modulation of apoptosis, ferroptosis, and endocannabinoid signaling in pancreatic cancer therapy. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 40790027
  47. Activation of CB2 Receptors by (-)-Cannabichromene but Not (+)-Cannabichromene. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 39137108
  48. The Oxidation of Phytocannabinoids to Cannabinoquinoids. mechanism-focused research / 1 linked research note PubMed 32315173
  49. Natural Cannabichromene (CBC) Shows Distinct Scalemicity Grades and Enantiomeric Dominance in Cannabis sativa Strains. evidence still limited / 1 linked research note PubMed 37023389
  50. Structure and Dynamics of Cannabinoid Binding to the GABAA Receptor. mechanism-focused research / 1 linked research note PubMed 40271542
  51. The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. animal study; mechanism-focused research / 1 linked research note PubMed 23373571
  52. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. animal study; mechanism-focused research / 1 linked research note PubMed 22300105
  53. Selected phytocannabinoids inhibit SN-38- and cytokine-evoked increases in epithelial permeability and improve intestinal barrier function in vitro. cell or laboratory study; evidence still limited / 1 linked research note PubMed 38950639
  54. In silico discovery of non-psychoactive scaffolds in Cannabis halting SARS-CoV-2 host entry and replication machinery. mechanism-focused research / 1 linked research note PubMed 35399958
  55. It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. narrative or expert review; evidence still limited / 1 linked research note PubMed 32899626
  56. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. animal study; mechanism-focused research / 1 linked research note PubMed 33230154
  57. Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. mechanism-focused research / 1 linked research note PubMed 19679411
  58. Cannabichromene attenuates fracture pain but impairs bone repair in a murine tibial fracture model. animal study; mechanism-focused research / 1 linked research note PubMed 41794091
  59. Modulatory Effects of "Minor" Cannabinoids in an in vitro Model of Neuronal Hypersensitivity. animal study; mechanism-focused research / 1 linked research note PubMed 41322279
  60. Efficient Synthesis for Altering Side Chain Length on Cannabinoid Molecules and Their Effects in Chemotherapy and Chemotherapeutic Induced Neuropathic Pain. animal study; mechanism-focused research / 1 linked research note PubMed 36551296
  61. Antinociceptive Effects of Cannabichromene (CBC) in Mice: Insights from von Frey, Tail-Flick, Formalin, and Acetone Tests. animal study; preclinical research / 1 linked research note PubMed 38255191
  62. Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. animal study; mechanism-focused research / 1 linked research note PubMed 20942863
  63. Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion. cell or laboratory study; evidence still limited / 1 linked research note PubMed 38885660
  64. Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation. evidence still limited / 1 linked research note PubMed 38889235
  65. Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 27094344
  66. Cannabis-Based Phytocannabinoids: Overview, Mechanism of Action, Therapeutic Application, Production, and Affecting Environmental Factors. narrative or expert review; evidence still limited / 1 linked research note PubMed 39457041
  67. Cannabinoids as Antibacterial Agents: A Systematic and Critical Review of In Vitro Efficacy Against Streptococcus and Staphylococcus. narrative or expert review; evidence still limited / 1 linked research note PubMed 39596719
  68. Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 35628241
  69. Cannabidiol and Minor Phytocannabinoids: A Preliminary Study to Assess Their Anti-Melanoma, Anti-Melanogenic, and Anti-Tyrosinase Properties. animal study; mechanism-focused research / 1 linked research note PubMed 37242431
  70. Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 36769042
  71. Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003-2017: part 1 - continuous bivariate analysis. evidence still limited / 1 linked research note PubMed 35354487
  72. Design and synthesis of amphiphilic cannabichromene derivatives with antimicrobial potential. evidence still limited / 1 linked research note PubMed 41202683
  73. Targeting the antioxidant, antimicrobial and anti-inflammatory activity of non-psychotropic Cannabis sativa L.: a comparison with chemotype V. evidence still limited / 1 linked research note PubMed 41121423
  74. Broad-spectrum bactericidal synergy of silver-cannabichromene-cannabigerol triple combinations against healthcare-associated pathogens. human research / 1 linked research note PubMed 41983582
  75. Synthetic Pathways to Non-Psychotropic Phytocannabinoids as Promising Molecules to Develop Novel Antibiotics: A Review. narrative or expert review; evidence still limited / 1 linked research note PubMed 37514074
  76. Spent Material Extractives from Hemp Hydrodistillation as an Underexplored Source of Antimicrobial Cannabinoids. evidence still limited / 1 linked research note PubMed 38927152
  77. Biological activity of cannabichromene, its homologs and isomers. animal study; preclinical research / 1 linked research note PubMed 7298870
  78. Therapeutic potential of phytocannabinoids in depression and cognitive dysfunction: Evidence from preclinical models. animal study; mechanism-focused research / 1 linked research note PubMed 41934896
  79. Cannabichromene Induces Neuronal Differentiation in NSC-34 Cells: Insights from Transcriptomic Analysis. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 36983897
  80. Antidepressant Effects of South African Plants: An Appraisal of Ethnobotanical Surveys, Ethnopharmacological and Phytochemical Studies. narrative or expert review; evidence still limited / 1 linked research note PubMed 35846999
  81. Cannabichromene, a key non-psychotropic phytocannabinoid in treatment of major depressive disorder: in silico and in vivo explorations. animal study; mechanism-focused research / 1 linked research note PubMed 40358684
  82. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. animal study; preclinical research / 1 linked research note PubMed 20332000
  83. The effect of cannabichromene on adult neural stem/progenitor cells. animal study; mechanism-focused research / 1 linked research note PubMed 23941747